Affron® - Supported by Clinical Studies
- neurodegenerative and cardiovascular disease prevention
- psychological symptoms in perimenopausal women
- improved anxiety and depressive symptoms in young people
- beneficial effects in recreationally active males
- sleep is enhanced
- reducing depressive and anxiolytic symptoms
- greater improvement in depressive symptoms
- more quickly bioavailable
Anxiety
A 2018 paper concluded that there were improved anxiety and depressive symptoms in young people with mild-to-moderate symptoms, at least from the perspective of the adolescent. However, these beneficial effects were inconsistently corroborated by parents.
Depression
Research from 2017 comprising differing doses of curcumin and combined curcumin/saffron were effective in reducing depressive and anxiolytic symptoms in people with major depressive disorder.
Research from 2019 concluded that adjunctive administration of a standardised saffron extract (affron®) for eight weeks was associated with a greater improvement in depressive symptoms as measured by the clinician-rated MADRS but not the self-report MADRS-S.
Mood
Research published in 2017 concluded that affron® increased mood, reduced anxiety and managed stress without side effects, offering a natural alternative to standard treatments.
Sleep
2021 published research suggests that sleep is enhanced after 28 days of supplementation in adults with unsatisfactory sleep building on the findings of an earlier study in 2018 and 2020.
Disease Prevention
A 2019 paper concluded that Affron® and ABG10+® would provide higher antioxidant activity for neurodegenerative and cardiovascular disease prevention respectively.
Menopause
Research from 2021 using affron® administered for 12 weeks was associated with greater improvements in psychological symptoms in perimenopausal women.
Exercise
2022 research concluded that the results of this trial suggest saffron may have beneficial effects in recreationally active males, as evidenced by increased exercise enjoyment and heart rate variability.
Disclaimer
These is a summary of published research but has not been evaluated by the European Food Safety Authority (EFSA) or other pertinent Regulatory Authority. This product is not intended to diagnose, treat, cure or prevent any disease.
Research from 2020 showed that the tested galenic form is an efficient way to administer a saffron extract, since the observed crocetin Cmax was similar and more quickly bioavailable than those obtained by other studies with much higher concentrations of crocetin.
